Exelixis stock has a good consolidation setup going into its earnings release on February 26, 2018.
Exelixis will be reporting earnings on February 26, 2018. Here is why this stock is a compelling setup.
Continue reading “Exelixis Coming Up On Earnings Release February 26 2018”
Gilead Sciences looks like a good oversold, candle over candle setup.
Gilead Sciences received approval from the FDA for Biktarvy, a once-daily combination of three drugs (bictegravir /emtricitabine/tenofovir alafenamide or BIC/FTC/TAF) for the treatment of HIV-1 infection. The company stands to reap up to a potential $5 billion in sales revenue from the approval.
Continue reading “Gilead Sciences Wins FDA Approval For Biktarvy”
Antares Pharma has had a few set backs over the years and investors have waited patiently for the company to turn a profit.
The chart of Ionis Pharmaceuticals doesn’t look like much but the fundamentals show eye-popping revenue growth.
Synergy Pharmaceuticals has a PDUFA ruling coming within the next couple of days. The Twiggs Money Flow has started to run ahead of the FDA announcement.
Ablynx stock is a late-stage clinical development company that is finally going to bring a product to market in Germany in 2018.